78 related articles for article (PubMed ID: 32747196)
1. Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis.
Colloca GA; Venturino A; Guarneri D
Pancreatology; 2020 Sep; 20(6):1189-1194. PubMed ID: 32747196
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy.
Colloca GA; Venturino A; Guarneri D
Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654
[TBL] [Abstract][Full Text] [Related]
3. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.
Colloca GA; Venturino A; Guarneri D
Med Oncol; 2018 Oct; 35(12):158. PubMed ID: 30374617
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
Haas M; Heinemann V; Kullmann F; Laubender RP; Klose C; Bruns CJ; Holdenrieder S; Modest DP; Schulz C; Boeck S
J Cancer Res Clin Oncol; 2013 Apr; 139(4):681-9. PubMed ID: 23315099
[TBL] [Abstract][Full Text] [Related]
6. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
7. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
Diaz CL; Cinar P; Hwang J; Ko AH; Tempero MA
Am J Clin Oncol; 2019 Dec; 42(12):898-902. PubMed ID: 31634155
[TBL] [Abstract][Full Text] [Related]
8. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.
Peixoto RD; Speers C; McGahan CE; Renouf DJ; Schaeffer DF; Kennecke HF
Cancer Med; 2015 Aug; 4(8):1171-7. PubMed ID: 25891650
[TBL] [Abstract][Full Text] [Related]
11. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Boeck S; Schulz C; Stieber P; Holdenrieder S; Weckbach S; Heinemann V
Onkologie; 2007 Feb; 30(1-2):39-42. PubMed ID: 17264524
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Kou T; Kanai M; Yamamoto M; Xue P; Mori Y; Kudo Y; Kurita A; Uza N; Kodama Y; Asada M; Kawaguchi M; Masui T; Mizumoto M; Yazumi S; Matsumoto S; Takaori K; Morita S; Muto M; Uemoto S; Chiba T
Int J Clin Oncol; 2016 Feb; 21(1):118-25. PubMed ID: 26123314
[TBL] [Abstract][Full Text] [Related]
13. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
14. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma.
Reni M; Cereda S; Balzano G; Passoni P; Rognone A; Fugazza C; Mazza E; Zerbi A; Di Carlo V; Villa E
Cancer; 2009 Jun; 115(12):2630-9. PubMed ID: 19353729
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
17. Elevated preoperative levels of CA 19-9 and CA 125 predicts overall survival time in the pancreatic adenocarcinoma. Single institution series.
Hogendorf P; Skulimowski A; Durczyński A; Kumor A; Poznańska G; Poznańska A; Oleśna A; Rut J; Øvereng Juliebø S; Szmiel A; Strzelczyk J
Pol Przegl Chir; 2020 Apr; 92(3):32-38. PubMed ID: 32759395
[TBL] [Abstract][Full Text] [Related]
18. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
[TBL] [Abstract][Full Text] [Related]
19. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy.
Bernhard J; Dietrich D; Glimelius B; Hess V; Bodoky G; Scheithauer W; Herrmann R
Br J Cancer; 2010 Oct; 103(9):1318-24. PubMed ID: 20877359
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
Micke O; Bruns F; Kurowski R; Horst E; deVries AF; Hausler JW; Willich N; Schäfer U
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):90-7. PubMed ID: 12909220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
